Savara Inc. Stock
€5.55
Your prediction
Savara Inc. Stock
Pros and Cons of Savara Inc. in the next few years
Pros
Cons
Performance of Savara Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Savara Inc. | - | 11.000% | 63.235% | 66.168% | 87.500% | 269.139% | 382.609% |
| Pacira Pharmaceuticals | 1.980% | 1.000% | 12.849% | 13.483% | 9.189% | -53.670% | -58.264% |
| Rockwell Medical Inc. | -7.730% | 3.154% | -3.416% | -58.916% | -58.631% | -9.838% | -92.418% |
| Twist Bioscience Corp | -1.080% | 7.737% | 5.966% | -44.491% | -39.405% | 11.129% | -76.316% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Savara Inc. (symbol: MSTX) operates within the pharmaceuticals sector, focusing on developing therapies for rare respiratory diseases. A financial review of Savara reveals a complex picture marked by significant challenges and a few commendable aspects. Overall, while the company's aim to address unmet medical needs is admirable, the financials highlight a precarious situation that could be concerning for investors.
Strong Market Capitalization: Savara boasts a market capitalization of approximately $649.9 million. This metric indicates a certain level of investor confidence and interest in the company, suggesting potential for further growth or development in its product pipeline.
Book Value: The book value per share stands at $0.882, which may suggest that the stock is trading under its intrinsic value. This can be attractive for value-oriented investors who believe that the stock price inadequately reflects the company's underlying assets.
News
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA).
Faruqi & Faruqi is a leading
